Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer

被引:0
作者
R D Kim
S R Alberts
C Peña
I Genvresse
A Ajavon-Hartmann
C Xia
A Kelly
J E Grilley-Olson
机构
[1] Moffitt Cancer Center,Department of Gastrointestinal Oncology
[2] Mayo Clinic,Department of Medical Oncology
[3] Bayer HealthCare Pharmaceuticals,Division of Hematology and Oncology
[4] Inc.,undefined
[5] Bayer AG,undefined
[6] University of North Carolina,undefined
来源
British Journal of Cancer | 2018年 / 118卷
关键词
copanlisib; gemcitabine; cisplatin; biliary tract cancer; phase Ib trial;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:462 / 470
页数:8
相关论文
共 206 条
[1]  
Ali A(2015)Effects of Cancer Genet 208 587-594
[2]  
Mishra PK(2011) gene alteration in patients with gallbladder cancer BMC Cancer 11 60-559
[3]  
Sharma S(2006)Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma Nat Methods 3 551-2178
[4]  
Arora A(2017)BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions Ann Oncol 28 2169-3905
[5]  
Saluja SS(2017)Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma J Clin Oncol 35 3898-65
[6]  
Deshpande V(2017)Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma Liver Cancer 6 59-664
[7]  
Nduaguba A(1981)Current status on cholangiocarcinoma and gallbladder cancer Clin Pharmacol Ther 29 658-9
[8]  
Zimmerman SM(2009)Clinical kinetics on intact cisplatin and some related species Mol Cancer Ther 8 1-803
[9]  
Kehoe SM(2016)Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy J Gastrointest Oncol 7 797-3847
[10]  
MacConaill LE(2016)Molecular profiling of biliary tract cancer: a target rich disease Cancer 122 3838-354